Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10963939 | Vaccine | 2015 | 5 Pages |
Abstract
Safety of vaccines can be compromised by contamination with adventitious agents. One potential source of adventitious agents is a vaccine seed, typically derived from historic clinical isolates with poorly defined origins. Here we generated synthetic poliovirus seeds derived from chemically synthesized DNA plasmids encoding the sequence of wild-type poliovirus strains used in marketed inactivated poliovirus vaccines. The synthetic strains were phenotypically identical to wild-type polioviruses as shown by equivalent infectious titers in culture supernatant and antigenic content, even when infection cultures are scaled up to 10-25Â L bioreactors. Moreover, the synthetic seeds were genetically stable upon extended passaging on the PER.C6® cell culture platform. Use of synthetic seeds produced on the serum-free PER.C6® cell platform ensures a perfectly documented seed history and maximum control over starting materials. It provides an opportunity to maximize vaccine safety which increases the prospect of a vaccine end product that is free from adventitious agents.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Barbara P. Sanders, Diana Edo-Matas, Natasa Papic, Hanneke Schuitemaker, Jerome H.H.V. Custers,